Urology
Volume 75, Issue 2 , Pages 257-261 , February 2010

Quantification of Carbonic Anhydrase IX Expression in Serum and Tissue of Renal Cell Carcinoma Patients Using Enzyme-linked Immunosorbent Assay: Prognostic and Diagnostic Potentials

  • Grace X. Zhou

      Affiliations

    • Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Joanna Ireland

      Affiliations

    • Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Patricia Rayman

      Affiliations

    • Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • James Finke

      Affiliations

    • Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Ming Zhou

      Affiliations

    • Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: Ming Zhou, M.D., Ph.D., Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH 44195

Received 31 May 2009 ,Accepted 24 September 2009.

References 

  1. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158:905–919
  2. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877–2888
  3. Wykoff CC, Pugh CW, Maxwell PH, et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene. 2000;19:6297–6305
  4. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004;64:6160–6165
  5. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811
  6. Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009;33:241–247
  7. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25:4757–4764
  8. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123:395–400
  9. Jensen HK, Nordsmark M, Donskov F, et al. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int. 2008;101(suppl 4):41–44
  10. Klatte T, Zomorodian N, Kabbinavar FF. Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma. J Clin Oncol. 2007;25(suppl 403s):abstract 4601
  11. Shah RB, Amin A, Braun T. High carbonic anhydrase (CA) IX protein tissue expression predicts response to interleukin (IL)-2 based therapy for advanced renal cell carcinoma patients. J Urol. 2007;75(suppl 243):abstract 725
  12. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714–3721
  13. Zavada J, Zavadova Z, Zat'Ovicova M, et al. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer. 2003;89:1067–1071
  14. Li G, Feng G, Gentil-Perret A, et al. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol. 2008;180:510–513
  15. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32:377–382
  16. Cohen D, Lane B, Jin T, et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer. 2007;5:264–270
  17. DeRoche T, Walker E, Magi-Galluzzi C, et al. Pathologic characteristics of solitary small renal masses: can they be predicted by preoperative clinical parameters?. Am J Clin Pathol. 2008;130:560–564

PII: S0090-4295(09)02677-6

doi: 10.1016/j.urology.2009.09.052

Urology
Volume 75, Issue 2 , Pages 257-261 , February 2010

Article Tools